OneSource Specialty Pharma jumps 21% in week on Ozempic ANDA

Stock rises in a weak tape

OneSource Specialty Pharma shares gained as much as 5% to ₹1,861.1 on the BSE during Friday’s intraday trade, even as the broader market stayed under pressure. Around 1:34 PM, the stock was up 4% at ₹1,833.05. Over the same period, the BSE Sensex was down 1.5% at 76,559. The divergence put the spotlight back on the small-cap pharmaceutical CDMO name after a sharp run-up over the last few sessions.

One-week rally and rebound from the low

In the past week, the stock rose 22%, outperforming the benchmark index which fell 2.5% during the same period. The stock has also rebounded 73% from its 52-week low of ₹1,075 touched on January 30, 2026. Separate market data in the same information set showed a 52-week range of ₹1,057 to ₹2,248, indicating the counter has already seen wide swings in the last year. The recent bounce has come after earlier volatility linked to quarterly results and regulatory timelines.

Trigger: tentative US FDA approval for generic Ozempic ANDA

A key near-term trigger cited by the company was an update dated April 21, 2026. OneSource Specialty Pharma said its partner Orbicular Pharmaceutical Technologies, along with a US-based front-end partner that holds the ANDA, secured tentative US Food and Drug Administration approval. The filing relates to an Abbreviated New Drug Application for a generic version of Ozempic, marketed as Semaglutide Injection. Tentative approval typically signals the application has met key review requirements, but final approval is still subject to outstanding conditions.

What OneSource does in the collaboration

OneSource described itself as the contract development and manufacturing organization partner for the product. The company said Orbicular led the product development and technical program for the complex peptide, while OneSource supported the program as the CDMO partner. Its role included end-to-end manufacturing capabilities for the US market filing. The collaboration is designed to ensure reliable commercial supply from OneSource’s US-FDA approved flagship site in Bangalore, according to the company.

Business profile: a pure-play specialty pharma CDMO

OneSource Specialty Pharma is positioned as a pure-play specialty pharmaceutical CDMO focused on complex products. It operates across biologics, drug-device combinations, sterile injectables, and oral technologies such as soft gelatin capsules. The company also describes itself as a multi-modality CDMO platform, with offerings in Drug Device Combinations including GLP-1, biologics, the SGC business, and sterile injectables. In FY25, the soft gel (SGC) and sterile injectable businesses were carved out from other promoter group companies and merged into OneSource.

Financial snapshot: FY25 surge, followed by softer 9M FY26

The company reported a sharp jump in total operating income in FY25, helped by milestone incomes from Manufacturing Service Agreements and the integration of the acquired businesses. Total operating income rose to ₹14,450 million in FY25 from ₹1,730 million in FY24. The company also reported a PBILDT margin of 32% for FY25.

In 9MFY26, total operating income came in at ₹9,930 million compared with ₹10,190 million in 9MFY25. PBILDT margin in 9MFY26 was 21.37%, down from 27.87% in 9MFY25. The article noted that despite steady-state contributions from the SGC and sterile injectables businesses, revenue and profitability declined year-on-year during the nine-month period.

Quarterly volatility: Q3 hit versus Q2 strength

The information set also references a sharp drawdown after a weak December quarter. OneSource shares fell 18% after the company reported a net loss of ₹470 million for the December quarter, versus a profit of ₹670 million in the prior-year quarter. Revenue for the quarter was reported at ₹2,903 million, down 26% year-on-year, with the company attributing the impact to delayed semaglutide approvals in Canada. EBITDA for the quarter was reported at ₹173 million, down 88% year-on-year from ₹1,420 million, while margins fell to 6% from 36%.

In contrast, Q2FY26 results cited in the same input showed revenue of ₹3,758 million, up 12% year-on-year. EBITDA was reported at ₹1,065 million, up 37% year-on-year, with an EBITDA margin of 28% and an expansion of about 506 basis points. Adjusted PAT stood at ₹449 million with adjusted EPS of ₹3.9. Management also said DDC capacity addition was being accelerated to support upcoming customer launches.

Technical setup, liquidity and market profile

A separate trading note for April 21, 2026 highlighted that the stock was trading above its 5-day, 20-day, 50-day and 100-day moving averages, but below the 200-day moving average. Delivery volume on April 20 fell 29.13% to 2.74 lakh shares versus the 5-day average, indicating lower investor participation in deliveries. The note also flagged a Mojo Score of 42.0 and a Mojo Grade of Sell, upgraded from Strong Sell on April 13, 2026.

The same note pegged market capitalisation at ₹17,570 crore and said liquidity was adequate for sizeable trades. It added that traded value represented about 2% of its 5-day average traded value, translating to a comfortable trade size capacity of around ₹2.46 crore. Other market snapshots in the input showed market cap figures around ₹17,745 crore and ₹18,468 crore, reflecting differences across data sources and timestamps.

Guidance and GLP-1 timeline referenced by the company

The article also flagged a positive outlook for the GLP-1 segment, with an expectation that it could yield revenue to the company from FY27 onwards. Separately, during the period of weak Q3 performance, the company reiterated FY28 guidance. It expects organic revenue of $100 million, which could rise to $100 million including the proposed acquisition. It also maintained EBITDA margin guidance at 40% and a net debt to EBITDA target below 1.5x.

Key facts at a glance

Other disclosures investors tracked

The information set includes a promoter pledge disclosure: Tenshi Pharmaceuticals Private Limited, a promoter entity, pledged 2,000,000 equity shares on December 16, 2025 for business and operational needs, with the company disclosing it on December 18, 2025 under SEBI regulations. It also references an ESOP allotment of 23,000 equity shares under the Employee Stock Option Plan 2021, taking paid-up share capital to ₹114.6 million. A separate Q1 FY26 snapshot cited revenue from operations of ₹3,272.70 million and a consolidated net loss of ₹1.86 million, along with exceptional items of ₹28.70 million tied to legal charges from subsidiary litigation linked to Sputnik vaccine matters.

Conclusion

OneSource Specialty Pharma’s latest rally has coincided with the April 21 update on tentative US FDA approval tied to a generic Ozempic ANDA involving its partner ecosystem and OneSource’s Bangalore manufacturing site. At the same time, recent financials show a mix of strong FY25 scaling and softer year-on-year performance in 9MFY26 and Q3. The next set of milestones for investors to track, as referenced in the disclosures, include progress on GLP-1 linked revenue expectations from FY27 onwards and developments tied to the company’s reiterated FY28 guidance and proposed acquisitions.